LWK1 Stock Overview
A biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
eFFECTOR Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.36 |
| 52 Week High | US$21.84 |
| 52 Week Low | US$9.30 |
| Beta | 0.52 |
| 11 Month Change | 0% |
| 3 Month Change | 0.31% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| LWK1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | -0.02% |
| 1Y | n/a | -17.2% | 8.2% |
Return vs Industry: Insufficient data to determine how LWK1 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how LWK1 performed against the German Market.
Price Volatility
| LWK1 volatility | |
|---|---|
| LWK1 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: LWK1 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine LWK1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 15 | Steve Worland | effector.com |
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer.
eFFECTOR Therapeutics, Inc. Fundamentals Summary
| LWK1 fundamental statistics | |
|---|---|
| Market cap | €57.93m |
| Earnings (TTM) | -€33.01m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.8x
P/E RatioIs LWK1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LWK1 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$35.81m |
| Earnings | -US$35.81m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.84 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -353.5% |
How did LWK1 perform over the long term?
See historical performance and comparison